Welcome to our dedicated page for BridgeBio Pharma SEC filings (Ticker: BBIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on BridgeBio Pharma's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into BridgeBio Pharma's regulatory disclosures and financial reporting.
BridgeBio Pharma director Scott Randal W. reported a mix of option exercises and share sales. On February 17, 2026, he exercised stock options for 10,000 shares of Common Stock at $16.75 per share and acquired the underlying shares.
That same day, he sold a total of 10,000 Common Stock shares in open-market transactions at weighted average prices within ranges of $73.74–$76.23 per share, pursuant to a Rule 10b5-1 sales plan adopted on June 27, 2025. After these transactions, he holds 14,896 shares directly and 4,000 shares indirectly through Thinking Bench Capital LLC.
Viking Global Investors and affiliated funds filed Amendment No. 10 to their Schedule 13D on BridgeBio Pharma, Inc. common stock. The reporting group discloses beneficial ownership of 13,026,367 shares, representing 6.8% of BridgeBio’s common stock, with shared voting and dispositive power over all reported shares.
The ownership percentage is calculated from 192,708,813 BridgeBio shares outstanding as of October 21, 2025, less 1,081,825 shares repurchased on January 21, 2026. The amendment updates the identity and structure of the Viking entities and individuals that may be deemed to share authority over this position and notes that recent transactions are listed in an attached exhibit.
BridgeBio Pharma (symbol BBIO) filed a notice of proposed stock sale under Rule 144. The filing covers up to 20,000 shares of common stock, with an aggregate market value of $1,505,000, to be sold through Morgan Stanley Smith Barney on NASDAQ around February 17, 2026.
The shares were acquired the same day through a cash exercise of stock options for 20,000 shares. The seller represents that they are not aware of any undisclosed material adverse information about the issuer’s current or prospective operations.
A holder of BridgeBio Pharma (BBIO) has filed a notice of proposed sale under Rule 144 covering 13,600 shares of common stock. The filing lists an aggregate market value of $1,016,147.12 for these shares, with 192,708,813 shares outstanding at the issuer. The shares were acquired as restricted stock from the issuer on 02/16/2025 and are expected to be sold around 02/17/2026 through Morgan Stanley Smith Barney LLC on the NASDAQ exchange.
Janus Henderson Group plc has filed a Schedule 13G showing beneficial ownership of 11,000,457 shares of BridgeBio Pharma, Inc. common stock, representing 5.7% of the class as of 12/31/2025.
The shares are held across multiple investment advisers within Janus Henderson that exercise investment and voting discretion for client accounts, called Managed Portfolios. Janus Henderson reports shared voting and shared dispositive power over all 11,000,457 shares, with no sole voting or dispositive power.
The filing states the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of BridgeBio. The Managed Portfolios receive all dividends and sale proceeds, and no individual Managed Portfolio holds more than five percent of BridgeBio’s common stock.
BridgeBio Pharma’s Chief Executive Officer, Kumar Neil, reported indirect open-market sales of the company’s common stock on February 10–11, 2026. The transactions were executed by the Kumar Haldea Family Irrevocable Trust and the Kumar Haldea Revocable Trust, where he serves as co-trustee, under a Rule 10b5-1 sales plan adopted on March 31, 2025. Individual trades included, for example, 14,201 shares sold at a weighted average price of $71.8018 per share and 7,806 shares at $70.6887 per share. After these sales, the trusts continued to hold large indirect positions, including 675,686 and 4,478,447 shares, and the Form 4 notes that the reporting person disclaims beneficial ownership beyond any pecuniary interest.
BridgeBio Pharma reported positive topline Phase 3 results from its PROPEL 3 trial of oral infigratinib in children with achondroplasia. The study met its primary endpoint, showing a statistically significant improvement in annualized height velocity at Week 52 (p<0.0001), with a mean treatment difference versus placebo of +2.10 cm/year and an LS mean of +1.74 cm/year.
The trial also met a key secondary endpoint, improving height Z-score, and showed the first statistically significant improvement in body proportionality versus placebo in children younger than 8 years. Oral infigratinib was generally well tolerated, with no treatment-related serious adverse events or discontinuations reported.
Based on these results, BridgeBio plans to submit a New Drug Application and Marketing Authorization Application for infigratinib for achondroplasia in the second half of 2026 and to accelerate development in hypochondroplasia, including ongoing and planned Phase 3 programs.
BridgeBio Pharma completed a private offering of $632.5 million in 0.75% Convertible Senior Notes due 2033 to qualified institutional buyers under Rule 144A. The notes pay 0.75% interest semiannually, mature on February 1, 2033, and can be settled in cash, stock, or a combination at the company’s election.
BridgeBio received approximately $619.3 million in net proceeds, which it plans to use mainly to repurchase, settle conversion obligations for, or repay a portion of its 2.50% Convertible Senior Notes due 2027, as well as for general corporate purposes. Concurrently with the closing, it used about $82.5 million of cash on hand to repurchase 1,081,825 shares of common stock at $76.26 per share from certain note purchasers.
The initial conversion rate is 9.0435 shares per $1,000 principal amount (an initial conversion price of about $110.58 per share), with potential adjustment and an increased rate in certain corporate events. A maximum of 8,293,972 shares may initially be issued upon conversion based on a maximum conversion rate of 13.1130 shares per $1,000 principal amount.
BridgeBio Pharma, Inc. insider activity centers on trusts associated with its Chief Executive Officer. A Form 4 reports that on January 8 and 9, 2026, the Kumar Haldea Family Irrevocable Trust and the Kumar Haldea Revocable Trust, for which the CEO is a co‑trustee, sold multiple blocks of BridgeBio common stock under a Rule 10b5‑1 sales plan adopted on March 31, 2025.
The reported weighted average sale prices for these transactions range from about $73.05 to $78.32 per share, with examples including 11,515 shares at a weighted average price of $73.6446 and 10,519 shares at $77.6086. Following the reported trades, the family irrevocable trust held 715,686 shares, the revocable trust held 4,518,447 shares, and 228,776 shares were held directly. The reporting person disclaims beneficial ownership of the trust‑held shares except to the extent of any pecuniary interest.
BridgeBio Pharma furnished an update with preliminary, unaudited financial figures for the quarter and fiscal year ended December 31, 2025. The company estimates it had approximately $587.5 million of cash, cash equivalents and marketable securities as of December 31, 2025. It also estimates net product revenue of $146.0 million for the fourth quarter of 2025 and $362.4 million for the full year 2025.
The company emphasized that these numbers are preliminary and subject to change as the year-end audit is completed. BridgeBio also presented a business update at the 44th Annual J.P. Morgan Healthcare Conference, and made its presentation slides available as an exhibit and on its website.